Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Mol Biol
2021 Mar 05;4335:166807. doi: 10.1016/j.jmb.2021.166807.
Show Gene links
Show Anatomy links
Identification of a Catalytic Active but Non-Aggregating MDM2 RING Domain Variant.
Magnussen HM
,
Huang DT
.
???displayArticle.abstract???
As a key regulator of the tumour suppressor protein p53, MDM2 is involved in various types of cancer and has thus been an attractive drug target. So far, small molecule design has primarily focussed on the N-terminal p53-binding domain although on-target toxicity effects have been reported. Targeting the catalytic RING domain of MDM2 resembles an alternative approach to drug MDM2 with the idea to prevent MDM2-mediated ubiquitination of p53 while retaining MDM2's ability to bind p53. The design of RING inhibitors has been limited by the extensive aggregation tendency of the RING domain, making it challenging to undertake co-crystallization attempts with potential inhibitors. Here we compare the purification profiles of the MDM2 RING domain from several species and show that the MDM2 RING domain of other species than human is much less prone to aggregate although the overall structure of the RING domain is conserved. Through sequence comparison and mutagenesis analyses, we identify a single point mutation, G443T, which greatly enhances the dimeric fraction of human MDM2 RING domain during purification. Neither does the mutation alter the structure of the RING domain, nor does it affect E2(UbcH5B)-Ub binding and activity. Hence, MDM2-G443T facilitates studies involving binding partners that would be hampered by the low solubility of the wild-type RING domain. Furthermore, it will be valuable for the development of MDM2 RING inhibitors.
Andreeff,
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
2016, Pubmed
Andreeff,
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
2016,
Pubmed
Berndsen,
A spectrophotometric assay for conjugation of ubiquitin and ubiquitin-like proteins.
2011,
Pubmed
Buetow,
Activation of a primed RING E3-E2-ubiquitin complex by non-covalent ubiquitin.
2015,
Pubmed
Cheng,
ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.
2009,
Pubmed
Coffill,
The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.
2016,
Pubmed
Dickens,
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.
2013,
Pubmed
Dolezelova,
Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers.
2012,
Pubmed
Dou,
Essentiality of a non-RING element in priming donor ubiquitin for catalysis by a monomeric E3.
2013,
Pubmed
Dou,
BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer.
2012,
Pubmed
Emsley,
Coot: model-building tools for molecular graphics.
2004,
Pubmed
Erba,
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.
2019,
Pubmed
Estrada-Ortiz,
How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.
2016,
Pubmed
Gu,
Regulation of XIAP translation and induction by MDM2 following irradiation.
2009,
Pubmed
Haupt,
Mdm2 promotes the rapid degradation of p53.
1997,
Pubmed
Itahana,
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.
2007,
Pubmed
Jones,
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
1995,
Pubmed
Kabsch,
XDS.
2010,
Pubmed
Kentsis,
Control of biochemical reactions through supramolecular RING domain self-assembly.
2002,
Pubmed
Khoo,
Drugging the p53 pathway: understanding the route to clinical efficacy.
2014,
Pubmed
Kussie,
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
1996,
Pubmed
Langheinrich,
Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling.
2002,
Pubmed
Linke,
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
2008,
Pubmed
Magnussen,
Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain.
2020,
Pubmed
Momand,
The MDM2 gene amplification database.
1998,
Pubmed
Montes de Oca Luna,
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
1995,
Pubmed
Murshudov,
REFMAC5 for the refinement of macromolecular crystal structures.
2011,
Pubmed
Nomura,
Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity.
2017,
Pubmed
Petitjean,
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
2007,
Pubmed
Poyurovsky,
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.
2007,
Pubmed
Ray-Coquard,
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
2012,
Pubmed
Rodriguez,
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
2000,
Pubmed
Roxburgh,
Small molecules that bind the Mdm2 RING stabilize and activate p53.
2012,
Pubmed
Storoni,
Likelihood-enhanced fast rotation functions.
2004,
Pubmed
Tan,
Anatomy of Mdm2 and Mdm4 in evolution.
2017,
Pubmed
Vonrhein,
Data processing and analysis with the autoPROC toolbox.
2011,
Pubmed
Winn,
Overview of the CCP4 suite and current developments.
2011,
Pubmed
Wu,
The p53-mdm-2 autoregulatory feedback loop.
1993,
Pubmed
Zhang,
Targeting p53-MDM2-MDMX loop for cancer therapy.
2014,
Pubmed
